ECSP003681A - Polymorphic salt - Google Patents

Polymorphic salt

Info

Publication number
ECSP003681A
ECSP003681A ECSP003681A ECSP003681A EC SP003681 A ECSP003681 A EC SP003681A EC SP003681 A ECSP003681 A EC SP003681A EC SP003681 A ECSP003681 A EC SP003681A
Authority
EC
Ecuador
Prior art keywords
polymorphic salt
migraine
prescribed
medicine
graph
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Ronald James Ogilvie
Arthur Bentley
Simon Arnold Howard-Fielo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003681A publication Critical patent/ECSP003681A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El presente invento trata de una forma polimórfica cristalina de un compuesto de fórmula (I) (gráfico), caracterizada por un diagrama de difracción de rayos X en polvo, obtenido al utilizar la radiación K-alfa del cobre(f = 0,15046 nm), que presenta picos principales a 9,28, 10,38, 11,37, 12,40, 16,84, 17,46, 17,53, 17,78, 17,98, 19,48, 20,70, 21,29, 21,45, 22,21, 22,64, 23,08, 25,20, y 25,79. El invento se refiere también a procedimientos para la preparación de dicha forma, a composiciones farmacéuticas que contienen la misma y a su uso en medicina, particularmente en el tratamiento de estados para los que se prescribe un agonista de recptores 5-HT, tales como, por ejemplo, la migraña.The present invention deals with a crystalline polymorphic form of a compound of formula (I) (graph), characterized by a powder X-ray diffraction diagram, obtained by using the copper's K-alpha radiation (f = 0,15046 nm ), which presents major peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70 , 21.29, 21.45, 22.21, 22.64, 23.08, 25.20, and 25.79. The invention also relates to processes for the preparation of said form, pharmaceutical compositions containing the same and their use in medicine, particularly in the treatment of conditions for which a 5-HT receptor agonist is prescribed, such as, by example, migraine.

ECSP003681 2000-09-25 2000-09-26 Polymorphic salt ECSP003681A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY26354A UY26354A1 (en) 2000-09-25 2000-09-25 POLYMORPHIC SALT

Publications (1)

Publication Number Publication Date
ECSP003681A true ECSP003681A (en) 2002-04-23

Family

ID=38812230

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003681 ECSP003681A (en) 2000-09-25 2000-09-26 Polymorphic salt

Country Status (2)

Country Link
EC (1) ECSP003681A (en)
UY (1) UY26354A1 (en)

Also Published As

Publication number Publication date
UY26354A1 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AU2014306149B2 (en) KDM1A inhibitors for the treatment of disease
ES2614934T3 (en) New crystalline form III of agomelatine, its preparation process and pharmaceutical compositions containing it
AR029570A1 (en) NEW GAMMA CRYSTAL FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CU23200A3 (en) Polymorphic salt
JO2793B1 (en) New Crystaline form V of Agomelatine, A process for It's Preparation and Pharmaceutical Compositions Containig it.
AR029571A1 (en) NEW BETA CRYSTALLINE FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
TW200736198A (en) New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HU229358B1 (en) Farnesyl protein transferase inhibitors for treating arthropathies
AR034124A1 (en) ALFA CRYSTAL FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
MA30464B1 (en) NEW CRYSTALLINE VI FORM OF AGOMELATIN, ITS PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
MX2009007669A (en) Substituted 1,3-dioxanes and their uses.
PE20030738A1 (en) SUCCINIC ACID SALTS OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
AR029347A1 (en) ADENINE COMPOUND, ISOGNANINE COMPOUND AND 2,6-DITIOXANTINE AS A PRECURSOR OF THE SAME, USE OF SUCH COMPOUNDS TO PREPARE A PHARMACEUTICAL COMPOSITION AND SUCH PHARMACEUTICAL COMPOSITION
CO2022006929A2 (en) Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
FR2981933B1 (en) OXOAZETIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN MEDICINE AND COSMETICS
PE20131327A1 (en) DELTA CRYSTAL FORM OF PERINDOPRYL ARGININE SALT, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
ECSP003681A (en) Polymorphic salt
AR029458A1 (en) ACTIVE COMPOUNDS IN THE GLUCOCORTICOID RECEIVER
ES2537792T3 (en) Anti-amnesic compounds and pharmaceutical compositions containing them
TH80938B (en) Salt
GB0114699D0 (en) Organic compounds
Hameed Electronic Structure of Some Chalcone Derivatives. I. Ground State Geometric Parameters and Charge Density Distributions, AM1-MO Treatment
TH158355A (en) New crystalline form of benzimidazole derivatives and their method of preparation.
TNSN05076A1 (en) New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
PE20081757A1 (en) [1- (4-TERC-BUTYLBENZYL) -5- (3-METHYLPHENYL) -1H-INDOL-3-IL] (OXO) ACETIC ACID POLYMORPHES